Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073411 · ClinicalTrials.gov registry record · Phase 3
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
A Phase 3 study of Depression, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 675
- Enrollment target
- 1
- Study location
NCT00073411: Completed Phase 3 study of Depression, sponsored by Eli Lilly and Company.
NCT00073411 is a Phase 3 study of Depression that has completed, run by Eli Lilly and Company. The registered enrollment target is 675 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073411, a Phase 3 study of Depression, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 675 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are to determine: * The safety of duloxetine and any side effects that might be associated with it. * How duloxetine compares to escitalopram and placebo (an inactive ingredient)
Conditions Studied
Interventions
- DRUG placebo
- DRUG duloxetine
- DRUG escitalopram
Study Locations (1)
Ohio
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 675 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
What the finished NCT00073411 record still lists
NCT00073411 is an interventional study that assigns participants to a tested intervention. The registered 675 participants enrollment target is mid-sized for trials with a published cap, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00073411 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00073411 about?
NCT00073411 is a clinical study titled "Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression". The purposes of this study are to determine: * The safety of duloxetine and any side effects that might be associated with it. * How duloxetine compares to escitalopram and placebo (an inactive ingredient)
What is the current status of trial NCT00073411?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2003-11. Estimated completion is 2005-05.
What conditions does trial NCT00073411 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00073411?
The interventions under investigation include: placebo (DRUG), duloxetine (DRUG), escitalopram (DRUG).
Who is sponsoring clinical trial NCT00073411?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073411 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00073411's enrollment target sits among peer trials
675 61st of 679 higher than 619 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- NCT05356234 · 675 participants · NA
Ignite Study of the Jewish Family and Children's Service of the Suncoast, Inc.
- NCT06070870 · 675 participants · NA
Health Education Approach to Lung Screening
- NCT06357533 · 675 participants · Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia